NCT03850678 is a NA clinical trial of Hearing Aid in Hearing Loss, sponsored by University of Nebraska Lincoln.

Who is sponsoring NCT03850678?

NCT03850678 is sponsored by University of Nebraska Lincoln.

What drugs are being tested in NCT03850678?

Interventions in NCT03850678: Hearing Aid.

What condition does NCT03850678 study?

NCT03850678 studies Hearing Loss.

Is NCT03850678 still recruiting?

NCT03850678 is currently completed. Last updated 14 January 2025.

Are results published for NCT03850678?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-14 · How we verify

NCT03850678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Restoration of Spectral Resolution With Hearing-aid Amplification

Completed NA Results posted Last updated 14 January 2025

What this trial tests

NA trial testing Hearing Aid in Hearing Loss in 209 participants. Completed in 30 November 2023.

Timeline

2 April 2019

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	University of Nebraska Lincoln
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	single
Primary purpose	treatment
Enrollment	209
Start date	2 April 2019
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across United States

Drugs / interventions tested

Hearing Aid

Conditions studied

Hearing Loss — all drugs for Hearing Loss →

Sponsor

University of Nebraska Lincoln

Who can join

Adults 40 to 75, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Spectral Resolution Primary · Each test was approximately 10 minutes and was completed after each experimental manipulation

Measure of spectral resolution (Q10) obtained from the fast psychophysical tuning curve test. For this study, Q10 was computed as the target frequency divided by the bandwidth of the tuning curve (10 dB above the threshold at the tip of the tuning curve test). Higher numbers on this scale indicate sharper (better) tuning. The lower limit for this scale is 0 and there is no upper limit.

Instant

Group	Value	95% CI
Hearing Aid Group	3.5	± 2.2

Fast

Group	Value	95% CI
Hearing Aid Group	3.3	± 1.9

Slow

Group	Value	95% CI
Hearing Aid Group	3.2	± 1.6

4 Channels

Group	Value	95% CI
Hearing Aid Group	2.8	± 1.2

8 Channels

Group	Value	95% CI
Hearing Aid Group	2.5	± 1.7

16 Channels

Group	Value	95% CI
Hearing Aid Group	3.5	± 1.1

Unaided

Group	Value	95% CI
Hearing Aid Group	2.7	± 1.7
Normal Hearing	3.9	± 2.0

Aided

Group	Value	95% CI
Hearing Aid Group	3.2	± 1.1

Speech Recognition Primary · Each test was approximately 10 minutes and was completed after each experimental manipulation

measure of spatial release from masking (dB) for a masker presented at 70 dB SPL.

unaided

Group	Value	95% CI
Normal Hearing	6.6	± 5.1
Hearing Aid	4.5	± 1.9

4 channels

Group	Value	95% CI
Hearing Aid	4.0	± 3.2

16 channels

Group	Value	95% CI
Hearing Aid	3.7	± 2.8

Working Memory Secondary · Each test was approximately 30 minutes and was completed only once per subject.

Measure of working memory (correctly repeated words from the reading span test). The minimum (poorer) and maximum (better) values are 0 and 57, respectively.

Group	Value	95% CI
Normal Hearing	23.6	± 6.8
Hearing Aid	20.1	± 7.4

Sponsor's own description

The objective of this study protocol is to determine the efficacy of using aided measures of spectral resolution to set the dynamic range of hearing with hearing-aid amplification. Measures of spectral resolution will be obtained, as will measures of speech recognition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Hearing Aid

Trials testing the same drug.

NCT04661995 — Notched Noise Therapy for Suppression of Tinnitus · NA · recruiting
NCT06128161 — Comparison of Unilateral CI vs. Bimodal Stimulation in Prosodic Perception · completed
NCT04147611 — Remote Microphone (RM) - A Comparative Study · NA · completed
NCT03867396 — Evaluation of Speech-in-noise Performance in Cochlear Implant Recipients With a CROS Device on the Contralateral Ear · NA · completed
NCT02951247 — Quality Control of CE-Certified Phonak Hearing Aids - 2016_05 · NA · completed

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other University of Nebraska Lincoln trials

Trials by the same sponsor.

NCT07160530 — Healthy Children, Healthy Communities: Effectiveness of a Multilevel Rural Community Engagement Model for Improving Chil · NA · recruiting
NCT06935435 — Effects of Distinct Nebraska-Dry Bean Market Classes on Gut Microbiota · NA · active not recruiting
NCT05873413 — Motivations, Attitudes, and Perceptions Study · NA · recruiting
NCT05988398 — Preventing Commercial Sexual Exploitation of Children · NA · completed
NCT05791825 — Evaluation of the CHIME Intervention for Improving Early Head Start/Head Start Educator Well-being · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03850678 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska Lincoln
Last refreshed: 14 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03850678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing